Royalty Pharma's Q4 results show portfolio receipts of $742 million and operating cash flow of $678 million. Read why RPRX ...

Many investors seemed to view Nvidia's decision to maintain its stake in Recursion as a vote of confidence in the company.

Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a ...

Royalty Pharma (RPRX) expects 2025 Portfolio Receipts to be between $2,900 million and $3,050 million, representing expected growth of 4% to ...

EST Recursion Pharmaceuticals (RXRX) files automatic mixed securities shelfMaximize Your Portfolio with Data Driven Insights:Leverage the ...

While technology is sometimes a hit-or-miss affair, particularly with the intrusions of innovation occasionally outweighing its conveniences, the best pharmaceutical stocks typically enjoy ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at ...

Explore the innovative world of 3D screen printing. Learn how this additive manufacturing technology from Axenoll and Exentis ...

Our calculations are based on comprehensive, delayed quotes. Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all ...

Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients ...